Alejandra Manjarrez, PhD | May 16, 2022 | 3 min read
A sugar that’s less abundant in the blood of people with diabetes binds to SARS-CoV-2’s spike protein and disrupts the virus’s ability to fuse with cells.
Researchers took aim at mucins, glycoproteins that protect cancer cells from drugs and the immune response, and engineered a revolutionary targeted tool for oncology and beyond.